U.S. FDA starts to review NDA of SK Biopharmaceuticals’ new sleep disorder treatment
SK Biopharmaceuticals(CEO Jung-Woo Cho) announced the company completed the New Drug Application(NDA) of SKL-N05(generic name: solriamfetol) that is being jointly developed with Jazz Pharmaceuticals, the world’s top pharmaceutical company in the sleep disorder market, for approval on December 201...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
